Tangen Jon-Magnus, Fløisand Yngvar, Haukås Einar, Naess Inger Anne, Skjelbakken Tove, Stapnes Camilla, Tjønnfjord Geir E
Avdeling for blodsykdommer, Oslo universitetssykehus, Ullevål, 0407 Oslo, Norway.
Tidsskr Nor Laegeforen. 2010 Sep 9;130(17):1710-3. doi: 10.4045/tidsskr.09.1293.
The Norwegian treatment protocol for acute lymphoblastic leukaemia in adults was introduced in 1982 and has undergone minor changes thereafter. Earlier studies from The South Eastern Norway Regional Health Authority have reported 50 % five-year overall survival in patients treated according to this protocol. This article presents survival data for Norwegian adults with acute lymphoblastic leukaemia on a national basis.
Data for all patients between 15 and 65 years, who were diagnosed with acute lymphoblastic leukaemia in the period 2000-2007 according to The Norwegian Registry for Acute Leukaemia and Lymphoblastic Lymphoma, and were treated with chemotherapy with a curative intent were analysed for survival.
128 patients were diagnosed with acute lymphoblastic leukaemia in the study period. The overall remission rate was 85.9 %. Five-year survival was 49.2 % overall, 31.4 % for patients 40 years or older and 62.6 % for those younger than 40 years.
These results are in line with previous Norwegian studies and show a five- year overall survival which is more than 10 % higher than that reported in international multicenter studies. One explanation can be that the Norwegian treatment program is more intensive than most treatment protocols used in other countries.
挪威成人急性淋巴细胞白血病治疗方案于1982年推出,此后经历了微小变化。挪威东南部地区卫生局早期的研究报告称,按照该方案治疗的患者五年总生存率为50%。本文介绍了挪威全国成人急性淋巴细胞白血病的生存数据。
分析了2000年至2007年期间根据挪威急性白血病和淋巴细胞淋巴瘤登记处诊断为急性淋巴细胞白血病、年龄在15至65岁之间且接受了根治性化疗的所有患者的生存数据。
在研究期间,128例患者被诊断为急性淋巴细胞白血病。总缓解率为85.9%。五年总生存率为49.2%,40岁及以上患者为31.4%,40岁以下患者为62.6%。
这些结果与挪威之前的研究一致,显示五年总生存率比国际多中心研究所报告的高出10%以上。一种解释可能是挪威的治疗方案比其他国家使用的大多数治疗方案更为强化。